TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19507292

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment
Number of subjects: 10720

Group type: EXPERIMENTAL
Intervention: Moderate to severe cognitive impairment
Number of subjects: 10720

Group type: EXPERIMENTAL
Intervention: Medium social engagement
Number of subjects: 10720

Group type: EXPERIMENTAL
Intervention: Low social engagement
Number of subjects: 10720

Group type: COMPARATOR
Intervention: Higher level of social engagement
Number of subjects: 10720
Study: 16779731

Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 724

Group type: COMPARATOR
Intervention: No enfuvirtide
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: R5 strains
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: D/M strains
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: X4 strains
Number of subjects: 724
Study: 15614460

Group type: EXPERIMENTAL
Intervention: 6 mg ivermectin (110 microg/kg) administered as a single dose, repeated 2 weeks later
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: 200 microg/kg ivermectin administered as a single dose, repeated 2 weeks later
Number of subjects: 409
Study: 12032393

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 8000 anti-FXa units LMWH Certoparin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous administration of 8000 anti-FXa units LMWH Certoparin
Number of subjects: 18
Study: 9640523

Group type: EXPERIMENTAL
Intervention: Experimental group (informed of cholesterol results after screening)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (informed of cholesterol results before screening)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Patients with abnormal cholesterol results
Number of subjects: 391
Study: 8033876

Group type: EXPERIMENTAL
Intervention: Condom-Foley catheter method (CFCM) with oxytocin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oxytocin infusion alone
Number of subjects: 45
Study: 2599730

Group type: EXPERIMENTAL
Intervention: Endurance training program with running a marathon, divided into three phases with training volumes of 45, 70, and 110 km/week.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Endurance training program with running a marathon.
Number of subjects: 114
Study: 785948

Group type: EXPERIMENTAL
Intervention: Haloperidol administered for 16 weeks
Number of subjects: 10
Study: 30611454

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (36 sessions over 12 weeks)
Number of subjects: 500

Group type: COMPARATOR
Intervention: PFMT plus solifenacin (5 mg/d over 36 weeks)
Number of subjects: 500
Study: 27282116

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (2000μg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vitamin D responsiveness classification
Number of subjects: 35
Study: 25494974

Group type: EXPERIMENTAL
Intervention: Acute sprint interval exercise (SIE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 8
Study: 22616628

Group type: COMPARATOR
Intervention: GSK679586 (0.005, 0.05, 0.5, 2.5, 10 mg kg(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK679586 (2.5, 10, 20 mg kg(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK679586
Number of subjects: 0
Study: 21818506

Group type: EXPERIMENTAL
Intervention: SRD174 cream
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 62
Study: 19514618

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study: 16430549

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 98
Study: 15262456

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 1213
Study: 11012239

Group type: EXPERIMENTAL
Intervention: SCAN-C Test for Auditory Processing Disorders in Children-Revised
Number of subjects: 650
Study: 8936586

Group type: EXPERIMENTAL
Intervention: Antiestrogen regimen (tamoxifen or toremifene)
Number of subjects: 38
Study: 1631876

Group type: EXPERIMENTAL
Intervention: Intraoperative blood temperature of 20 degrees C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intraoperative blood temperature of 28 degrees C
Number of subjects: 20
Study: 6431795

Group type: EXPERIMENTAL
Intervention: sublingual isosorbide dinitrate (ISDN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nitroglycerin (NTG)
Number of subjects: 10
Study: 31968059

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 640
Study: 31177581

Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius K12 plus nystatin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo plus nystatin
Number of subjects: 56
Study: 28368738

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 7359

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 7359
Study: 26799892

Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention program including one Skype session and six weeks of daily directive text messages guiding app use.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (details not specified).
Number of subjects: 0
Study: 23181710

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.05% + Fluoride 0.05%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22077909

Group type: EXPERIMENTAL
Intervention: Abciximab plus unfractionated heparin
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 1721
Study: 18754096

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg every 24 h
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg every 12 h (q12h)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 80 mg q12h
Number of subjects: 26
Study: 17005051

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study: 14684622

Group type: EXPERIMENTAL
Intervention: Intervention group (100 physicians) received individual visits up to three times over a 2-year period with educational material and personal laboratory test utilization data.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (100 physicians) did not receive the intervention.
Number of subjects: 200
Study: 10707752

Group type: EXPERIMENTAL
Intervention: High dose captopril (50 mg b.i.d.)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Low dose captopril (25 mg b.i.d.)
Number of subjects: 298
Study: 9226142

Group type: EXPERIMENTAL
Intervention: Nonparametric bootstrap method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fieller theorem method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taylor series method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Box method
Number of subjects: 0
Study: 1357516

Group type: EXPERIMENTAL
Intervention: Guaifenesin (2400 mg daily for 3 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3907494

Group type: EXPERIMENTAL
Intervention: Oxacillin plus rifampin (12 g/day, intravenously; rifampin 1,200 mg/day, orally)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oxacillin plus placebo (12 g/day, intravenously)
Number of subjects: 101
Study: 2439344

Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimen (methotrexate 30 mg/m2, bleomycin 15 mg, hydroxyurea 1000 mg/m2, cisplatin 60 mg/m2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 3-drug combination (methotrexate 30 mg/m2, bleomycin 15 mg, hydroxyurea 1000 mg/m2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimen
Number of subjects: 62
Study: 31411903

Group type: EXPERIMENTAL
Intervention: Behavioral Consultation (BC)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No Behavioral Consultation (NoBC)
Number of subjects: 127
Study: 29389467

Group type: EXPERIMENTAL
Intervention: Pre-competition massage
Number of subjects: 17

Group type: COMPARATOR
Intervention: Dynamic warm-up
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of massage and warm-up
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 17
Study: 27136409

Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 46
Study: 25900644

Group type: EXPERIMENTAL
Intervention: Objective symptoms
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Subjective symptoms
Number of subjects: 362
Study: 23070803

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 450
Study: 21112549

Group type: EXPERIMENTAL
Intervention: Radachlorin® solution for intravenous infusions 0.35% 10mL at doses of 0.5‐0.6 and 1.0‐1.2mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radachlorin® gel for topical application 0.1% 25g at a dose of 0.1g/cm(2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug administration at a dose of 1.0‐1.2mg/kg and irradiation at 3h with 662±3nm light at a dose of 300J/cm(2) (solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 PDT sessions at an interval of 1 week with 3h gel exposure, followed by 400J/cm(2) light exposure (gel)
Number of subjects: 0
Study: 18257397

Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 16801295

Group type: EXPERIMENTAL
Intervention: Community-organizing approach to restrict retail sale of tobacco to youth for 32 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control communities (no specific intervention)
Number of subjects: 14
Study: 14606076

Group type: EXPERIMENTAL
Intervention: Hepatectomy with splenectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hepatectomy without splenectomy
Number of subjects: 26
Study: 11003362

Group type: EXPERIMENTAL
Intervention: EOS-guided steroid dose adjustment (RG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No EOS monitoring (NG)
Number of subjects: 80
Study: 8872667

Group type: EXPERIMENTAL
Intervention: Air rich in CO2 (CO2 exposure)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 4
Study: 1523144

Group type: EXPERIMENTAL
Intervention: 20 mg buscopan
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 40 mg papaverine
Number of subjects: 41

Group type: COMPARATOR
Intervention: 2 ml of 0.9% NaCl solution
Number of subjects: 41
Study: 6478752

Group type: EXPERIMENTAL
Intervention: Breathing 60% oxygen
Number of subjects: 5

Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 5
Study: 30666153

Group type: EXPERIMENTAL
Intervention: BP-C1 (0.035 mg/kg bodyweight, daily intramuscular injection for 32 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (equal-looking, for 32 days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BP-C1 (after crossover from placebo)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BP-C1
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29947688

Group type: EXPERIMENTAL
Intervention: Single port laparoscopic cholecystectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 57
Study: 27634487

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g kg-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Calcium carbonate (PLA)
Number of subjects: 10
Study: 24828266

Group type: EXPERIMENTAL
Intervention: Minitab sprinkles (40 mg/10 mg)
Number of subjects: 77
Study: 21710355

Group type: EXPERIMENTAL
Intervention: Group C (then-test questions included)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Group B (transition questions included)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Group A (post-test questions only)
Number of subjects: 949
Study: 20462897

Group type: EXPERIMENTAL
Intervention: Time to stable ST-segment reperfusion (TSTR)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: TSTR cutoff value of 136.5 minutes
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Killip class > or = 2
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Final TIMI flow grade III
Number of subjects: 137
Study: 18558645

Group type: EXPERIMENTAL
Intervention: IPT‐MOMS (n=26)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment as usual (n=21)
Number of subjects: 47
Study: 16858935

Group type: EXPERIMENTAL
Intervention: Roselle flower tea (RFT) administered at 4,000 mg in 480 ml of hot distilled water
Number of subjects: 0
Study: 11824237

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (thermal, mechanical, and injection procedures)
Number of subjects: 0
Study: 9541732

Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol and 0.5% pale sulfonated shale oil
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Alcoholic vehicle
Number of subjects: 91
Study: 7804294

Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3134556

Group type: EXPERIMENTAL
Intervention: Oxamniquine 60 mg/kg
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Oxamniquine 40 mg/kg
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Oxamniquine 20 mg/kg
Number of subjects: 296

Group type: COMPARATOR
Intervention: Oxamniquine (all doses)
Number of subjects: 296
Study: 30928925

Group type: EXPERIMENTAL
Intervention: Low-energy meal replacement diet (average ≈810 kcal/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Guideline-directed clinical care with lifestyle coaching
Number of subjects: 90
Study: 28607070

Group type: EXPERIMENTAL
Intervention: Decentralized communication networks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Centralized networks
Number of subjects: 0
Study: 26468074

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 25 μg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Epidural meperidine 25 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Epidural clonidine 2 μg/kg
Number of subjects: 135
Study: 24529670

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.1 mg/kg/hour)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 21377295

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 μg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19694865

Group type: EXPERIMENTAL
Intervention: Intervention toolkit including admission form with geriatric cues, facsimile to the primary care provider, interdisciplinary worksheet, pharmacist-physician collaborative medication reconciliation, predischarge planning appointments.
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Intervention toolkit
Number of subjects: 185
Study: 17507345

Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet (40% carbohydrate and 35% fat)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Low-fat diet (55% carbohydrate and 20% fat)
Number of subjects: 73
Study: 15254060

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg/d to 1,800 mg/d)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 121
Study: 11229465

Group type: EXPERIMENTAL
Intervention: Intraarticular glucocorticoid treatment (120 mg of methylprednisolone acetate)
Number of subjects: 40
Study: 9751468

Group type: EXPERIMENTAL
Intervention: 50 mg methylprednisolone in mepivacaine 0.25%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mepivacaine (placebo)
Number of subjects: 20
Study: 7908257

Group type: EXPERIMENTAL
Intervention: 10 mg SL 84.0418
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg SL 84.0418
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg SL 84.0418
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3391876

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid
Number of subjects: 2

Group type: COMPARATOR
Intervention: Erythromycin base (EB) 500 mg tid
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 500 mg tid
Number of subjects: 2
Study: 29910837

Group type: EXPERIMENTAL
Intervention: LMWF‐5A
Number of subjects: 168

Group type: COMPARATOR
Intervention: Saline (historical control)
Number of subjects: 168
Study: 27248436

Group type: EXPERIMENTAL
Intervention: Educational intervention based on social learning theory and the Health Belief Model (HBM)
Number of subjects: 3570

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 3570
Study: 25624132

Group type: EXPERIMENTAL
Intervention: 200 μg/d of nasal fluticasone propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23826101

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and docetaxel 75 mg/m2 (Epi/Doc)
Number of subjects: 30
Study: 21628653

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 860
Study: 19433683

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² plus carboplatin AUC = 5 on day 1
Number of subjects: 436

Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m² on days 1 and 8 plus carboplatin AUC = 5 on day 1
Number of subjects: 436
Study: 16969059

Group type: EXPERIMENTAL
Intervention: Primaquine 30 mg once daily for 7 days (group A, n = 71)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Elubaquine 25 mg once daily for 7 days (group B, n = 70)
Number of subjects: 141
Study: 15590356

Group type: EXPERIMENTAL
Intervention: Enalaprilat infusion (0.06 mg/kg/hr) during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (dopamine infusion only)
Number of subjects: 30
Study: 11704167

Group type: EXPERIMENTAL
Intervention: 49-day cycle (42 active pills)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 28-day cycle (21 active pills)
Number of subjects: 90
Study: 8961507

Group type: EXPERIMENTAL
Intervention: PFP-2 vaccine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2145238

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 10
Study: 478062

Group type: EXPERIMENTAL
Intervention: Sterosan-hydrocortison ointment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sterosan ointment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sterosan cream
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oral administration of chlorquinaldol
Number of subjects: 3
Study: 31811627

Group type: EXPERIMENTAL
Intervention: Single-session empathetic communication skills training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 82
Study: 30699438

Group type: EXPERIMENTAL
Intervention: Real-time fMRI-guided neurofeedback training to enhance connectivity between the ventrolateral prefrontal cortex (vlPFC) and the amygdala
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham control pathway
Number of subjects: 26
Study: 27704590

Group type: EXPERIMENTAL
Intervention: Incredible Years® Toddler Parenting Programme
Number of subjects: 89
Study: 25705958

Group type: EXPERIMENTAL
Intervention: Oxymorphone Hydrochloride (OH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propoxyphene/Acetaminophen (PA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24581076

Group type: EXPERIMENTAL
Intervention: Therapist-led, synchronous groups using live chat
Number of subjects: 102
Study: 22182419

Group type: EXPERIMENTAL
Intervention: Behavioral treatments for adolescent marijuana abuse or dependence
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Delay discounting task for $100 and $1,000 of hypothetical money and marijuana
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Demographic variables (socioeconomic status, race)
Number of subjects: 165
Study: 20835896

Group type: EXPERIMENTAL
Intervention: LAGB at optimal volume
Number of subjects: 17

Group type: COMPARATOR
Intervention: LAGB empty
Number of subjects: 17
Study: 17948223

Group type: EXPERIMENTAL
Intervention: Surgery followed by uracil-tegafur 360 mg/m²/day for 16 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 190
Study: 15606304

Group type: EXPERIMENTAL
Intervention: mFISH analysis of plutonium-exposed subjects
Number of subjects: 0
Study: 11867823

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 250 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10438349

Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen 10 U
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen 2.5 U
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen
Number of subjects: 10
Study: 8885737

Group type: EXPERIMENTAL
Intervention: Surgical assist device (SutureMate)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Usual fashion (control arm)
Number of subjects: 476
Study: 1948598

Group type: EXPERIMENTAL
Intervention: 0.5 per cent bupivacaine plus epinephrine 1 to 200,000
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5 per cent bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study: 6222086

Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 0.1 mg/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 0.5 mg/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 1.0 mg/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Discontinuation of oral 13-cis-retinoic acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clinical response to treatment
Number of subjects: 20